Kwak Hee-Jin, Park Myung-Jin, Park Chang-Min, Moon Sang-Ik, Yoo Doo-Hyun, Lee Hyung-Chahn, Lee Seung-Hoon, Kim Mi-Suk, Lee Hyean-Woo, Shin Woon-Seob, Park In-Chul, Rhee Chang Hun, Hong Seok-Il
Laboratory of Functional Genomics, Korea Institute of Radiological and Medical Sciences, Seoul, Korea.
Int J Cancer. 2006 Jun 1;118(11):2711-20. doi: 10.1002/ijc.21641.
Emodin (1,3,8-trihydroxy-6-methylanthraquinone), an active component in the root and rhizome of Rheum palmatum, is a tyrosine kinase inhibitor with a number of biological activities, including antitumor effects. Here, we examine the effects of emodin on vascular endothelial growth factor (VEGF)-A-induced angiogenesis, both in vitro and in vivo. In vitro, emodin dose-dependently inhibits proliferation, migration into the denuded area, invasion through a layer of Matrigel and tube formation of human umbilical vein endothelial cells (HUVECs) stimulated with VEGF-A. Emodin also inhibits basic fibroblast growth factor-induced proliferation and migration of HUVECs and VEGF-A-induced tube formation of human dermal microvascular endothelial cells. Specifically, emodin induces the cell cycle arrest of HUVECs in the G0/G1 phase by suppressing cyclin D1 and E expression and retinoblastoma protein phosphorylation, and suppresses Matrigel invasion by inhibiting the basal secretion of matrix metalloproteinase-2 and VEGF-A-stimulated urokinase plasminogen activator receptor expression. Additionally, emodin effectively inhibits phosphorylation of VEGF-A receptor-2 (KDR/Flk-1) and downstream effector molecules, including focal adhesion kinase, extracellular signal-regulated kinase 1/2, p38 mitogen-activated protein kinase, Akt and endothelial nitric oxide synthase. In vivo, emodin strongly suppresses neovessel formation in the chorioallantoic membrane of chick and VEGF-A-induced angiogenesis of the Matrigel plug in mice. Our data collectively demonstrate that emodin effectively inhibits VEGF-A-induced angiogenesis in vitro and in vivo. Moreover, inhibition of phosphorylation of KDR/Flk-1 and downstream effector molecules is a possible underlying mechanism of the anti-angiogenic activity of emodin. Based on these data, we propose that an interaction of emodin with KDR/Flk-1 may be involved in the inhibitory function of emodin toward VEGF-A-induced angiogenesis in vitro and responsible for its potent anti-angiogenic in vivo.
大黄素(1,3,8 - 三羟基 - 6 - 甲基蒽醌)是掌叶大黄根及根茎中的一种活性成分,是一种具有多种生物活性(包括抗肿瘤作用)的酪氨酸激酶抑制剂。在此,我们研究了大黄素在体外和体内对血管内皮生长因子(VEGF)-A诱导的血管生成的影响。在体外,大黄素呈剂量依赖性地抑制VEGF - A刺激的人脐静脉内皮细胞(HUVECs)的增殖、迁移至裸露区域、穿过一层基质胶的侵袭以及管腔形成。大黄素还抑制碱性成纤维细胞生长因子诱导的HUVECs增殖和迁移以及VEGF - A诱导的人真皮微血管内皮细胞的管腔形成。具体而言,大黄素通过抑制细胞周期蛋白D1和E的表达以及视网膜母细胞瘤蛋白磷酸化,诱导HUVECs在G0/G1期的细胞周期停滞,并通过抑制基质金属蛋白酶 - 2的基础分泌和VEGF - A刺激的尿激酶型纤溶酶原激活剂受体表达来抑制基质胶侵袭。此外,大黄素有效抑制VEGF - A受体 - 2(KDR/Flk - 1)及其下游效应分子的磷酸化,这些下游效应分子包括粘着斑激酶、细胞外信号调节激酶1/2、p38丝裂原活化蛋白激酶、Akt和内皮型一氧化氮合酶。在体内,大黄素强烈抑制鸡绒毛尿囊膜中的新血管形成以及小鼠基质胶栓中VEGF - A诱导的血管生成。我们的数据共同表明,大黄素在体外和体内均有效抑制VEGF - A诱导的血管生成。此外,抑制KDR/Flk - 1及其下游效应分子的磷酸化是大黄素抗血管生成活性的一种可能潜在机制。基于这些数据,我们提出大黄素与KDR/Flk - 1的相互作用可能参与了大黄素在体外对VEGF - A诱导的血管生成的抑制作用,并负责其在体内强大的抗血管生成作用。